Regeneron Pharmaceuticals achieved FDA accelerated approval for Lynozyfic (linvoseltamab), a bispecific antibody targeting BCMA and CD3 in multiple myeloma, marking a significant milestone in oncologic therapeutics. Concurrently, studies elucidate critical immune mechanisms in cancer, such as mast cell-mediated enhancement of MAIT cell tumor-fighting capacity via IL-18 secretion and the role of tumor-specific lymphocytes targeted by radiation in head and neck cancers. These insights and approvals advance personalized and immune-focused cancer therapies.